ENZASTAURIN VERSUS LOMUSTINE IN THE TREATMENT OF RECURRENT, INTRACRANIAL GLIOBLASTOMA: A PHASE III STUDY

被引：0
|
作者：
Puduvalli, Vinay K. [1 ]
Wick, Wolfgang [2 ]
Chamberlain, Marc [3 ]
Carpentier, Antoine [4 ]
Cher, Lawrence
Mason, Warren [5 ]
Van Den Bent, Martin [6 ]
Hong, Sam
Thornton, Donald E. [7 ]
Fine, Howard [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Heidelberg, Heidelberg, Germany
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Hop La Pitie Salpetriere, Serv Neurol Mazarin, Paris, France
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Erasmus Canc Ctr, Rotterdam, Netherlands
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] NCI, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [1] Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
    Wick, Wolfgang
    Puduvalli, Vinay K.
    Chamberlain, Marc C.
    van den Bent, Martin J.
    Carpentier, Antoine F.
    Cher, Lawrence M.
    Mason, Warren
    Weller, Michael
    Hong, Shengyan
    Musib, Luna
    Liepa, Astra M.
    Thornton, Donald E.
    Fine, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1168 - 1174
  • [2] ENZASTAURIN (ENZ) VERSUS LOMUSTINE (CCNU) IN THE TREATMENT OF RECURRENT, INTRACRANIAL GLIOBLASTOMA (GBM): A PHASE III STUDY
    Wick, W.
    Puduvalli, V. K.
    Chamberlain, M.
    Carpentier, A.
    Cher, L.
    Mason, W.
    Van den Bent, M.
    Hong, S.
    Thornton, D.
    Fine, H.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1068 - 1068
  • [3] Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study
    Fine, H. A.
    Puduvalli, V. K.
    Chamberlain, M. C.
    Carpentier, A. F.
    Cher, L.
    Mason, W. P.
    van den Bent, M. J.
    Hong, S.
    Thornton, D.
    Wick, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
    Batchelor, Tracy T.
    Mulholland, Paul
    Neyns, Bart
    Nabors, L. Burt
    Campone, Mario
    Wick, Antje
    Mason, Warren
    Mikkelsen, Tom
    Phuphanich, Surasak
    Ashby, Lynn S.
    DeGroot, John
    Gattamaneni, Rao
    Cher, Lawrence
    Rosenthal, Mark
    Payer, Franz
    Juergensmeier, Juliane M.
    Jain, Rakesh K.
    Sorensen, A. Gregory
    Xu, John
    Liu, Qi
    van den Bent, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3212 - 3218
  • [5] THE EFFICACY OF CEDIRANIB AS MONOTHERAPY AND IN COMBINATION WITH LOMUSTINE COMPARED TO LOMUSTINE ALONE IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A PHASE III RANDOMIZED STUDY
    Batchelor, Tracy
    Mulholland, Paul
    Neyns, Bart
    Nabors, L. B.
    Campone, Mario
    Wick, Antje
    Mason, Warren
    Mikkelsen, Tom
    Phuphanich, Surasek
    Ashby, Lynn S.
    DeGroot, John F.
    Gattamancni, H. R.
    Cher, Lawrence M.
    Rosenthal, Mark A.
    Payer, Franz
    Xu, John
    Liu, Qi
    van den Bent, Martin
    NEURO-ONCOLOGY, 2010, 12 : 75 - 75
  • [6] A PHASE III RANDOMIZED STUDY COMPARING THE EFFICACY OF CEDIRANIB AS MONOTHERAPY, AND IN COMBINATION WITH LOMUSTINE, WITH LOMUSTINE ALONE IN RECURRENT GLIOBLASTOMA PATIENTS
    Batchelor, T.
    Mulholland, P.
    Neyns, B.
    Nabors, L. B.
    Campone, M.
    Wick, A.
    Mason, W.
    Xu, J.
    Liu, Q.
    van den Bent, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 4 - 4
  • [7] A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
    Taal, Walter
    Oosterkamp, Hendrika M.
    Walenkamp, Annemiek M. E.
    Beerepoot, Laurens Victor
    Hanse, Monique
    Buter, J.
    Honkoop, Aafke
    Boerman, Dolf
    De Vos, Filip Yves Francine Leon
    Jansen, Rob L.
    van den Berkmortel, Franchette W. P. J.
    Brandsma, Dieta
    Kros, Johan M.
    Bromberg, Jacoline E.
    van Heuvel, Irene
    Smits, Marion
    van der Holt, Bronno
    Vernhout, Rene
    Van den Bent, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma
    Brandes, Alba Ariela
    Carpentier, Antoine F.
    Kesari, Santosh
    Sepulveda, Juan
    Wheeler, Helen
    Chinot, Olivier L.
    Cher, Lawrence
    Steinbach, Joachim Peter
    Specenier, Pol
    Cleverly, Ann
    Smith, Claire
    Gueorguieva, Ivelina
    Guba, Susan C.
    Desaiah, Durisala
    Lahn, Michael M. F.
    Wick, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize
    Galanis, Evanthia
    Buckner, Jan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1097 - 1098
  • [10] Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU)
    van den Bent, M. J.
    Wick, W.
    Liepa, A. M.
    Puduvalli, V. K.
    Carpentier, A. F.
    Cher, L.
    Mason, W. P.
    Taphoorn, M. J.
    Hong, S.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345